AMLX - Amylyx pulls ALS therapy Relyvrio from the market
2024-04-04 07:32:38 ET
More on Amylyx Pharmaceuticals
- An ALS Drug Fails Again
- Amylyx Pharmaceuticals: Q4 Earnings Insight And PHOENIX Trial Implications
- Amylyx Pharmaceuticals, Inc. (AMLX) Q4 2023 Earnings Call Transcript
- Mizuho downgrades Amylyx to Neutral after ALS trial setback
- Amylyx crashes as late-stage ALS trial for Relyvrio fails